# Deciphering the code: the pivotal role of lncRNAs in advancing TNBC therapy

## TL;DR

This paper reviews how long non-coding RNAs (lncRNAs) influence triple-negative breast cancer (TNBC) and could lead to better diagnosis and treatment.

## Contribution

The paper highlights novel roles of lncRNAs in TNBC progression and their potential as therapeutic targets.

## Key findings

- lncRNAs regulate gene expression in TNBC through nuclear and cytoplasmic mechanisms.
- Aberrant lncRNA expression patterns are linked to TNBC progression and chemotherapy response.
- lncRNAs offer new opportunities for early diagnosis and precision medicine in TNBC.

## Abstract

Triple-negative breast cancer (TNBC) represents the most formidable subtype of breast cancer, characterized by a notable dearth in targeted therapeutic options. Deciphering the underlying molecular mechanisms of TNBC is pivotal for improving patient outcomes. Recent scientific advancements have spotlighted long non-coding RNAs (lncRNAs) as key players in the genesis, progression, and metastasis of cancers. This review delineates the significant influence of lncRNAs on the advancement, detection, and neoadjuvant chemotherapy efficacy in TNBC, detailing the diverse expression patterns of aberrant lncRNAs. The paper explores the specific mechanisms by which lncRNAs regulate gene expression in both the nucleus and cytoplasm, with a special focus on their involvement in TNBC’s post-transcriptional landscape. Thorough investigations into TNBC-associated lncRNAs not only forge new avenues for early diagnosis and potent treatment strategies but also highlight these molecules as promising therapeutic targets, heralding an era of personalized and precision medicine in TNBC management.